A nice demonstration of that advantage for detection of cancer-associated mutations has recently been provided by Bando et al. [43] who performed multiplex single tube testing for 36 mutations in KRAS, NRAS, BRAF and PIK3CA. Unfortunately, they did not provide any data on the analytical sensitivity of the assay. This evidence concerns the gene NRAS and cancer.